Has your health system prepared for HRSA’s forthcoming 340B Rebate Model Pilot Program, scheduled to begin January 1, 2026? We have. At the bottom of this post, you’ll find a detailed overview of exactly how our 340B team has prepared to help the 340B health systems we serve — including a short-term loan program we’ll … Read More
Since 2019, VytlOne has supported the 340B programs of more than 100 health systems and health centers. We’ve published dozens of posts exploring 340B topics and trends — major, minor and developing. Recently, we were asked by a reader to produce a post offering our thoughts on, and predictions for, the program’s future. If there … Read More
How can this unprecedented manufacturer restriction generate the company, OR patients, a net benefit? It would not be an exaggeration to say that Bausch Health (BHC) sent shockwaves through much of the healthcare industry in declaring its intention to cease participation in what it deemed two “optional” Federal drug pricing programs — the Medicaid Drug … Read More
Since late 2019, VytlOne has supported the 340B programs of 33 health systems and 38 health centers. Altogether, we’ve generated nearly $1 billion in pharmacy-related savings for our clients. We analyze 340B program-savings potential for dozens of prospective clients every year. And not once have we ever served, or encountered, a health system capable of … Read More
Download Our Free Compliance Checklist PDF 340B health systems have been under increasing scrutiny and regulatory oversight in recent years. The Health Resources and Services Administration (HRSA) has indicated that it plans to increase the number and complexity of 340B program audits it conducts. Here’s how your health system can prepare every aspect of … Read More
Fair Warning: If you ever dismissively ask that question (above) of someone who’s led the planning and launch of a 340B hospital’s specialty pharmacy, and did it with no outside support, there’s a good chance you’ll get punched. Yes, it’s that difficult. POST OUTLINE Why is it so hard to build a 340B specialty … Read More
The evolving legal and legislative landscape surrounding the 340B Drug Pricing Program has significant implications for hospitals’ specialty pharmacies. Here’s a breakdown of the new developments and their likely impacts: Recent 340B changes and their impact on specialty pharmacies 1. 340B contract pharmacy restrictions Drug manufacturers have increasingly restricted the use of contract pharmacies, especially … Read More
Maximizing pharmacy’s role in your hospital’s revenue cycle The 340B landscape continues to evolve rapidly, with ongoing manufacturer restrictions, new compliance hurdles, and increasing financial pressures on covered entities. The average 340B-eligible hospital loses a substantial amount of money due to drug manufacturer restrictions on the program. Recent estimates indicate that hospitals and clinics collectively … Read More
POST OUTLINE Introduction: Overview Review of Johnson & Johnson’s drug rebate payments in 2023 J&J’s 2023 profit margin Johnson & Johnson’s real rebate problem 340B and the drug industry as a whole Estimated percentage of drug sales supporting 340B health systems Why the actual number is lower than reported The importance of 340B savings & … Read More
POST OUTLINE PHASE ONE: Organizing 340B data, coordinating teams Connecting and educating 340B system providers Requalifying all eligible, but unreimbursed, 340B scripts Retrieving 340B eligible-script data Establishing communication lines between internal and external 340B teams Why specialized software is essential for successful 340B programs The central problem with most 340B programs’ data Why 340B software … Read More
